Cytokinetics announces publication of omecamtiv mecarbil in the GALACTIC-HF trial in European Journal of Heart Failure.

Cytokinetics, Incorporated announced that a manuscript detailing the baseline characteristics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase III event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, was published in the European Journal of Heart Failure. Omecamtiv mecarbil, a selective cardiac myosin activator, is being developed for the potential treatment of heart failure with reduced ejection fraction under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier. GALACTIC-HF is designed to evaluate whether treatment with omecamtiv mecarbil, dosed twice-daily in accordance with a pharmacokinetic-guided dose optimization regimen, when added to standard of care, reduces the risk of heart failure events (heart failure hospitalization or other urgent, unscheduled treatment for heart failure) and cardiovascular (CV) death in patients with chronic heart failure and reduced ejection fraction (HFrEF). Patients enrolled in GALACTIC-HF were required to have a diagnosis of HFrEF with left ventricular ejection fraction (LVEF) ?35% and elevated natriuretic peptides. Patients were either currently hospitalized for heart failure (25% of total enrollment), or had a recent hospitalization, or a visit to an emergency room or urgent care facility for heart failure within the preceding year. See-Teerlink JR, Diaz R, Felker GM, McMurray JJ, Metra M, Solomon SD, Adams KF, Anand I, Arias?Mendoza A, Biering?Sørensen T, Böhm M, Bonderman D, Cleland JGF, et al.,. "Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC?HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials". Eur J Heart Fail. 2020. Accepted Author Manuscript. doi:10.1002/ejhf.2015.